Skip to content
10-Q

Quarterly Report

Oncternal Therapeutics, Inc.

0000950170-23-062132

← back to feed
Filed
Nov 9, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 3, 2023 58.97M sh
Short Term Investments Q3 2023 · Sep 30, 2023 $25.38M
Short Term Investments Q3 2023 · Dec 31, 2022 $26.58M
Cash And Equivalents Q3 2023 · Sep 30, 2023 $14.93M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $37.14M
Current Liabilities Q3 2023 · Sep 30, 2023 $5.15M
Current Liabilities Q3 2023 · Dec 31, 2022 $7.68M
Total Liabilities Q3 2023 · Sep 30, 2023 $6.2M
Total Liabilities Q3 2023 · Dec 31, 2022 $7.68M
Current Assets Q3 2023 · Sep 30, 2023 $42.49M
Current Assets Q3 2023 · Dec 31, 2022 $67.29M
Total Assets Q3 2023 · Sep 30, 2023 $43.2M
Total Assets Q3 2023 · Dec 31, 2022 $68.65M
Shares Diluted Q3 2023 · Sep 30, 2022 54.21M sh
Shares Diluted Q3 2023 · Sep 30, 2022 51.25M sh
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$27.7M
Stockholders Equity Q3 2023 · Sep 30, 2022 $68.54M
Stockholders Equity Q3 2023 · Jun 30, 2022 $74M
Stockholders Equity Q3 2023 · Dec 31, 2021 $88.12M
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.21
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.64
Eps Basic Q3 2023 · Sep 30, 2022 −$0.21
Eps Basic Q3 2023 · Sep 30, 2022 −$0.64
Net Income Q3 2023 · Sep 30, 2022 −$11.13M
Net Income Q3 2023 · Sep 30, 2022 −$32.77M
Operating Income Q3 2023 · Sep 30, 2022 −$11.33M
Operating Income Q3 2023 · Sep 30, 2022 −$33.03M
Revenue Q3 2023 · Sep 30, 2022 $382K
Revenue Q3 2023 · Sep 30, 2022 $1.32M